For more than 20 years, Atuka has been providing preclinical services that expand the frontiers of Parkinson’s disease research, and helping to make new, life-changing therapeutics a reality.
Atuka provides its partners with the highest-quality studies and data, as interpreted by world-leading neuroscientists, to ensure results that are consistently predictive and translatable.
Atuka’s lead scientists are responsible for numerous breakthroughs that have helped shape the direction of research in the field over the past three decades. Collectively they have published more than 300 peer-reviewed, highly-cited papers, and individually possess h-indices ranging from 25 to 70.
therapeutics evaluated
candidates proceeding to clinical trial
peer-reviewed academic papers
pre-clinical models
WHITE PAPER
Strategies to optimize preclinical study design for therapeutic development and reduce translational risk.
As Parkinson’s becomes the fastest-growing neurological disorder worldwide, its rising prevalence raises urgent questions about public health and economic impact. Could improved diagnosis, treatment, and life expectancy offer a hidden silver lining within the statistics?
At the annual summit of the Society for Neuroscience in Chicago, it was clearer than ever that collaboration and advancing technologies are central to moving the field forward.
Insights from Atuka’s recent visit to the 6th Annual Inflammasome Summit in Boston.
Building on Atuka’s pioneering work in Parkinson’s disease and other neurodegenerative disorders, this paper lays out the transformative potential of gene therapy.
—
MEET THE ATUKA TEAM
As a rec league basketball player—not to mention diehard Toronto Raptors fan— Andrea-Kaye Datu is the closest thing Atuka has to a point guard both on and off the court. Off the court, at Atuka, Andre…
Read More
For many of Atuka’s partners, scientist Tielli Magnus M.Sc. is their first point of contact when initiating a preclinical study. “I work with the client to sort out and manage all of the details once …
Read More
At Atuka’s facility in Suzhou, China, the team that Su Jin oversees as operations manager conducts both small and large scale non-human primate studies for our partners around the world. Born just an …
Read MoreSERVICES & CAPABILITIES
Expanding the frontiers of research into neurodegenerative disorders
While our roots are in Parkinson’s research, Atuka has developed extensive preclinical experience developing therapies for numerous other indications—including cognitive disorders, ALS and other movement disorders such as dystonia and dyskinesia—across multiple modalities, such as biologics (including gene therapy) and small molecules.
Redefining innovation
Atuka is unique among contract research organizations. Not only do we provide our partners with industry-leading expertise in preclinical trial design and interpretation, but we are committed to ongoing scientific discovery in Parkinson’s disease and other disorders through an extensive internal research program, while actively contributing to and engaging with the scientific literature.
Working at Atuka means contributing everyday to the development trajectories of potentially life-changing therapeutics, supported by world-class facilities and scientists, and an industry-leading benefits plan. Our mission-driven team is diverse both in background and expertise, bringing to every one of our partner engagements a spirit of close collaboration, along with a commitment to the highest ethical standards in scientific research.
Our sites and facilities
Our partners benefit from globally-recognized scientists using advanced technologies at leading-edge research and lab facilities in Canada and China.
Atuka is a world expert in NHP research and has the capacity to conduct both small and large studies that use up to 150 macaques at our newly renovated, AAALAC-accredited facility in Suzhou, China. We are able to perform studies no other CRO can, while adhering to the highest standards of animal welfare.
With a depth of preclinical experience unparalleled in our field globally, Atuka has collaborated with over 90 organizations, including large pharmaceutical and biotech companies, charitable foundations, universities, and government agencies.
TALK TO OUR EXPERTS
Sign up to receive our quarterly newsletter featuring the latest developments in Parkinson’s disease research.